Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499172 | 0.87 | GPR132 (0.41) | OPRK1SMN1; SMN2 | |
| SCHEMBL15762738 | 0.87 | OPRK1 (0.43) | OPRK1PTPN1KMT2AMEN1MAPT | |
| SCHEMBL16154942 | 0.87 | OPRK1 (0.43) | OPRK1PTPN1KMT2AMEN1MAPT | |
| SCHEMBL8403375 | 0.86 | CYSLTR2 (0.42) | ALOX5LMNASMN1; SMN2HPGD | |
| SCHEMBL29731126 | 0.85 | FKBP1A (0.46) | — | |
| SCHEMBL499202 | 0.85 | OPRK1 (0.40) | OPRK1 | |
| SCHEMBL15049104 | 0.85 | FKBP1A (0.46) | — | |
| SCHEMBL21643439 | 0.85 | OPRK1 (0.40) | OPRK1 | |
| SCHEMBL499106 | 0.85 | FKBP1A (0.46) | — | |
| SCHEMBL16158169 | 0.85 | FKBP1A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-0776327-B1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | OPRK1 3363/4885PTPN1 949/4885ALOX5 3920/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | OPRK1 3496/4885PTPN1 440/4885ALOX5 4272/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | OPRK1 3284/4885PTPN1 466/4885ALOX5 4406/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | OPRK1 3433/4885PTPN1 770/4885ALOX5 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.